{"id":296050,"date":"2025-05-26T00:00:00","date_gmt":"2025-05-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0019-2020-biopharma-psoriasis-current-treatment-current-treatment-physician-insights\/"},"modified":"2026-03-31T10:26:05","modified_gmt":"2026-03-31T10:26:05","slug":"cutrim0019-2025-biopharma-psoriasis-current-treatment-current-treatment-physician-insights-psoriasis-eu5","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0019-2025-biopharma-psoriasis-current-treatment-current-treatment-physician-insights-psoriasis-eu5\/","title":{"rendered":"Psoriasis &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Psoriasis (EU5)"},"content":{"rendered":"<p>The psoriasis treatment landscape has significantly evolved in the past few years. A plethora of psoriasis treatments are available in the <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, ranging from topical agents to conventional systemic therapies (e.g., methotrexate, cyclosporine), biologics, and oral targeted therapies (e.g., Amgen\u2019s Otezla, Bristol Myers Squibb\u2019s Sotyktu). The availability of biosimilars of adalimumab and ustekinumab further expands dermatologists\u2019 treatment armamentarium. However, the abundance of options has increased the complexity of physicians\u2019 prescribing decisions. In this report, we offer insight into dermatologists\u2019 prescribing patterns, attitudes and perceptions, and current and anticipated use of various products. We also offer insight on the perceived advantages and disadvantages of these products, as well as the sales and messaging efforts of key market players.<\/p>\n<p><strong>Questions answered <\/strong><\/p>\n<ul class=\"BulletListStyle1 SCXW139445303 BCX0 round-bullets\">\n<li>Which drugs are the patient-share leaders in different lines of therapy? How are Otezla and Sotyktu positioned in surveyed physicians\u2019 psoriasis treatment algorithm?<\/li>\n<li>What are the most influential drivers of treatment selection, and under which scenarios do\/will physicians prescribe ustekinumab biosimilars and Bimzelx?<\/li>\n<li>How long do patients stay on a therapy? What factors drive therapy discontinuation and switching?<\/li>\n<li>How and why has dermatologists\u2019 prescribing changed in the past year? What changes are they anticipating in the coming year?<\/li>\n<\/ul>\n<p><strong>Markets covered: <\/strong>France, Germany, Italy, Spain, and the United Kingdom<\/p>\n<p><strong>Primary research:<\/strong> 250 dermatologists completed the survey. Of these physicians, 50 were in France, 50 in Germany, 50 in Italy, 50 in Spain, and 50 in the United Kingdom. The survey was fielded <a>in March 2025.<\/a><\/p>\n<p><strong>Key companies:<\/strong> AbbVie, Johnson &#038; Johnson Innovative Medicine, Eli Lilly, UCB, Amgen, Bristol Myers Squibb<\/p>\n<p><strong>Key drugs: <\/strong>Humira, Stelara, biosimilar ustekinumab, Taltz, Bimzelx, Tremfya, Skyrizi, Otezla, Sotyktu<\/p>\n<p><strong>Product description <\/strong><\/p>\n<p>Through survey data from <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr> physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW139445303 BCX0 round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<li>Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-296050","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-product-current-treatment","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296050\/revisions"}],"predecessor-version":[{"id":575783,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296050\/revisions\/575783"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}